Shots:
- Algiax reported topline data from the P-IIa PoC trial assessing AP-325 (GABA-A modulator) vs PBO in 99 pts with peripheral post-surgical neuropathic pain in Germany, Spain, the Czech Republic, Belgium, & France
- Data showed rapid PI-NRS reduction in <2wks., sustained effects, plus significantly higher ≥50% & ≥70% responder rates with ~25% vs. 11% pts showing pain reduction of ≥50%
- In addition, AP-325 showed a favorable NNT with opioid-like efficacy but no related side effects & >50% pts avoided rescue therapy in contrast to 21% on PBO. Improvements in sleep, anxiety & depression scores were also observed
Ref: Businesswire | Image: Algiax
Related News:- Daiichi Sankyo and AstraZeneca Dose the First Patient with Adjuvant Datroway in P-III (TROPION-Lung12) Trial for Adenocarcinoma NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
